Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
The user is considering adding a scalp massager to their current hair loss treatments, which include finasteride, minoxidil, pumpkin seed oil, and microneedling. They are seeking advice on whether to invest in a scalp massager or remain patient with their current regimen.
Hairgenetix Copper Peptide Serum and PeptideLabz GHK-Cu + AHK-Cu Serum are being compared for effectiveness in hair loss treatment. The user is seeking recommendations for other brands with authentic reviews.
The conversation discusses the effectiveness of AMSbzs supplements in significantly increasing hair count, weight, and keratin content. The user questions why this treatment isn't more widely known despite its impressive results.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.
The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.
The post discusses using Sandalore as a potential hair loss treatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.
A 27-year-old male is using a hair loss treatment regimen including topical minoxidil, oral finasteride, dermarolling, ketoconazole shampoo, and mesotherapy with dutasteride and vitamins. He is considering switching to oral dutasteride as recommended by his doctor and questions the necessity and cost of mesotherapy.
User experienced scarring from microneedling at fast speed and paused treatment for 3-4 weeks to recover. Advice given includes waiting a full month for recovery to avoid scars.
Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.
A user decided to use a hair system after 10 years of hair loss, avoiding surgery and supplements due to potential side effects. They were nervous but hopeful for natural-looking results.
A user shared their positive experience with a non-surgical hair replacement system, detailing the purchase and maintenance process, including using Walker Lace Front Support Tape and various adhesives. They found the system secure and undetectable, allowing them to engage in active pursuits without issues.
Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
The conversation discusses concerns about MVSupplements.com products, specifically the Min+Ru spray and GHK Serum, due to discrepancies in ingredient lists and recent poor feedback. Users also mention a price increase and one user reports no issues with the RU powder.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
HairClone plans to start hair multiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.